Torsdag 20 Augusti | 13:15:54 Europe / Stockholm
Svenska | English
Est. tid*
2026-10-29 07:40 Kvartalsrapport 2026-Q3
2026-08-20 07:40 Kvartalsrapport 2026-Q2
2026-05-21 - X-dag halvårsutdelning VISTN 1
2026-05-20 - Årsstämma
2026-04-24 - Kvartalsrapport 2026-Q1
2026-02-12 - Bokslutskommuniké 2025
2025-10-31 - Kvartalsrapport 2025-Q3
2025-08-15 - Kvartalsrapport 2025-Q2
2025-06-04 - X-dag ordinarie utdelning VISTN 1.25 NOK
2025-05-22 - Årsstämma
2025-04-25 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-11-06 - X-dag halvårsutdelning VISTN 0.5
2024-10-31 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-06-05 - X-dag halvårsutdelning VISTN 0.5
2024-05-23 - Årsstämma
2024-04-24 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2024-01-23 - X-dag ordinarie utdelning VISTN 0.75 NOK
2023-10-25 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-23 - X-dag ordinarie utdelning VISTN 0.00 NOK
2023-05-22 - Årsstämma
2023-04-27 - Kvartalsrapport 2023-Q1
2023-02-17 - Bokslutskommuniké 2022
2022-10-26 - Kvartalsrapport 2022-Q3
2022-08-19 - Kvartalsrapport 2022-Q2
2022-05-24 - X-dag ordinarie utdelning VISTN 0.00 NOK
2022-05-19 - Årsstämma
2022-04-27 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-21 - X-dag ordinarie utdelning VISTN 0.50 NOK
2021-05-20 - Årsstämma
2021-04-23 - Kvartalsrapport 2021-Q1
2021-02-19 - Bokslutskommuniké 2020
2020-10-30 - Kvartalsrapport 2020-Q3
2020-08-28 - Kvartalsrapport 2020-Q2
2020-06-24 - Extra Bolagsstämma 2020
2020-05-20 - X-dag ordinarie utdelning VISTN 1.00 NOK
2020-05-19 - Årsstämma
2020-04-23 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-10-25 - Kvartalsrapport 2019-Q3
2019-08-29 - Kvartalsrapport 2019-Q2
2019-05-23 - X-dag ordinarie utdelning VISTN 0.00 NOK
2019-05-22 - Årsstämma
2019-04-25 - Kvartalsrapport 2019-Q1
2019-02-19 - Bokslutskommuniké 2018
2018-10-25 - Kvartalsrapport 2018-Q3
2018-08-30 - Kvartalsrapport 2018-Q2
2018-05-25 - X-dag ordinarie utdelning VISTN 1.00 NOK
2018-05-08 - Årsstämma
2018-04-26 - Kvartalsrapport 2018-Q1
2018-02-27 - Bokslutskommuniké 2017
2017-11-03 - X-dag bonusutdelning VISTN 7
2017-11-02 - Extra Bolagsstämma 2017
2017-10-27 - Kvartalsrapport 2017-Q3
2017-08-31 - Kvartalsrapport 2017-Q2
2017-05-26 - X-dag ordinarie utdelning VISTN 1.00 NOK
2017-05-24 - Årsstämma
2017-04-26 - Kvartalsrapport 2017-Q1
2017-02-28 - Bokslutskommuniké 2016
2016-10-31 - Kvartalsrapport 2016-Q3
2016-08-30 - Kvartalsrapport 2016-Q2
2016-05-25 - X-dag ordinarie utdelning VISTN 0.60 NOK
2016-05-24 - Årsstämma
2016-04-28 - Kvartalsrapport 2016-Q1
2016-02-23 - Bokslutskommuniké 2015
2015-10-29 - Kvartalsrapport 2015-Q3
2015-08-26 - Kvartalsrapport 2015-Q2
LandNorge
ListaOslo Bors
SektorHälsovård
IndustriLäkemedel & Handel
Vistin Pharma är ett norskt läkemedelsbolag. Bolaget bedriver forskning och utveckling samt vidare produktion av farmaceutiska substanser (API), främst substanserna metformin, kodein fosfat och folkodin. Substanserna används huvudsakligen vid behandling av diabetes. Bolaget är verksamt på global nivå, med störst närvaro på den nordiska marknaden. Vistin Pharma grundades 2015 och har sitt huvudkontor i Oslo.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Vistin Pharma ASA: Second quarter and YTD 2026 financial results

2026-08-20 07:45:00

Oslo, Norway, 20 August 2026

Vistin Pharma ASA (VISTN) today announces its financial results for the second quarter and first half of 2026.

Revenue in the second quarter amounted to MNOK 100, compared to MNOK 118 in Q2 2025. Sales volume increased by 8%, offset by a significantly stronger NOK against EUR in the quarter compared to 2025, impacting sales in local currency.

Revenue for the first half of 2026 amounted to MNOK 212, compared to MNOK 233 in the corresponding period of 2025, representing a decrease of 9%. On a currency-neutral basis, revenue declined by 3% during the period.

EBITDA for the second quarter was MNOK 22, compared to MNOK 30 in Q2 2025. Adjusted for currency effects, EBITDA decreased by approximately MNOK 2. The EBITDA margin was 22% in the quarter.

For the first half of 2026, EBITDA amounted to MNOK 49, compared to MNOK 60 in the same period of 2025.

Net profit for the second quarter was MNOK 14.1, compared to MNOK 18.4 in Q2 2025. The net debt position at the end of June was MNOK 8. During the quarter the Company paid an ordinary cash dividend of NOK 1.0 per share, corresponding to approximately MNOK 44.

“We are pleased to continue our sales volume growth in 2026 versus 2025 (+8% / 240MT). The Vistin Sales & Marketing team is actively working in new regions of the world to offer our products, and onboard new customers whilst our manufacturing team is steadily working on ramping up capacity.”
Magnus Tolleshaug, CEO

The second quarter presentation and conference call will be held today, 20 August 2026 at 08:30 CEST, and will be accessible through the following channels:

Webcast: https://edge.media-server.com/mmc/p/abe93pzc

Telephone conference (online registration):
https://register-conf.media-server.com/register/BIca3298faa94f4bbb900f07289bc40eb7

The conference call will be conducted in English.   

The Q2 report and presentation are attached to this announcement. The report and a recording of the webcast will also be available on www.vistin.com.

*****

For further information, please contact:

Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


Attachments

Vistin Pharma ASA Q2 presentation 2026
Vistin Pharma ASA Q2 report 2026

Källa GlobeNewswire Nordic
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Företag
Pressmeddelanden